Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Argos Therapeutics
ARGS

Buy Argos Therapeutics (ARGS) Stock

ARGS
See ARGS stock price and Buy/Sell Argos Therapeutics with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
ARGS

Argos Therapeutics (ARGS)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Argos Therapeutics (ARGS)

Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmu...Read more
Market Cap
$567.4k
1 Year High
$0.25
Volume
1 Year Low
$0.02
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch ARGS stock

Argos Therapeutics stock rating

What analysts recommend for ARGS stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell

Argos Therapeutics price target

What analysts think ARGS will be worth
Low $0
High $0.25
Current $0
Target $0

Argos Therapeutics earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.6
-1.2
-1.8
Q4 2018

Expected EPS
Q4 2018
-$1.80
Actual EPS
Q4 2018

Buy Argos Therapeutics (ARGS) Stock

ARGS
See ARGS stock price and Buy/Sell Argos Therapeutics with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch ARGS stock
  • sclark084 avatar
  • christifa avatar
  • mauro5607 avatar
  • najjakd1234 avatar
  • chriscam2 avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.